Navitoclax, a member of the B-cell lymphoma 2 (BCL-2) family of protein inhibitors, was shown to induce apoptosis in cancer cells by disrupting the interactions between BCL-2-like proteins and BH3 domains [53]. This evidence concerns the gene BCL2 and cancer.